articleThe Lancet NeurologyJul 31, 2008Closed access

Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial

LLLars LannfeltKBKaj BlennowHZHenrik ZetterbergSBStellan BåtsmanDADavid Ames

Uppsala University Hospital · Sahlgrenska University Hospital · +8 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

707
total citations
FWCI
33.77
Percentile
100%
References
32
Citations per year

Authors

12

Topics & keywords

Topics
Keywords
  • Tolerability
  • Placebo
  • Medicine
  • Internal medicine
  • Adverse effect
  • Pathology
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.